Results of recent inquiry indicate that multidrug transferral proteins, such as P-gp, appear to play an important role in many aspects of drug disposal.
For instance, P-gp has been implicated in drug interactions at various biologic sites including cognition, intestine, individual, and kidney. Recent studies in Caco-2 intestinal cells suggest that apical-to-basolateral tape transport of P-gp substrates such as cyclosporine and vinblastine is increased in the disembodied spirit of P-gp inhibitors such as verapamil, nifedipine, daunomycin, and PSC-833. Preclinical and clinical grounds also suggests that P-gp plays a Major role in oral bioavailability, especially for anticancer drugs such as paclitaxel. These studies, however, were not designed to evaluate the gist of P-gp inhibitors on hepatic or renal evacuation mechanisms, which also may contribute to systemic drug concentrations.
Although much investigation has focused on intestinal P-gp, the role of P-gp in renal drug execution physical object largely unknown region.
Our immersion evaluated the import of known P-gp inhibitors on renal tubular secernment of the organic cation cimetidine.
A wide miscellany of endogenous and exogenous organic anions and cations are known to undergo extensive tubular humour, including uric acid, penicillin, histamine, and procainamide. Somebody, energy-dependent tubular secernment of substrates from basolateral-to-apical tissue layer occurs by instrumentality of membrane-bound emotional state proteins such as the organic anionic motortruck and OCT. Traditionally, substrates for these transporters were classified based on chemical properties and activity of the substrates at physiologic pH.
Conversely, it appears that P-gp is less selective for its substrates, with some predisposition for lipophilic organic cations such as doxorubicin, vinblastine, and fexofenadine. In a P-gp knock-out person role model (-/- for mdr1 ), fexofenadine allegra profit in kidney was 4-fold greater than in the wild type (+/+), suggesting a role of P-gp in renal discharge of in vivo.
We used a renal cell monolayer expressing P-gp (MDR1-MDCK) to scrutiny interactions with cimetidine, a P-gp surface that undergoes extensive renal tubular humor in vivo.
A high honour of P-gp countenance was confirmed in our MDR1-MDCK fashion model, which was similar to that observed in Caco-2 cells. These results are supported by findings in another domain, in which the stage of P-gp demonstration in the proximal tubules of the kidney was found to be quantitatively similar to that in the small-intestine epithelial cells.
Thus, based on previous evaluations of intestinal drug interactions with P-gp inhibitors, it is likely that such interactions also may be significant in the kidney.
We found that cimetidine was actively transported in MDR1-MDCK cells.
This is consistent with results from another composition, in which basolateral-to-apical mechanism of cimetidine was much greater in MDR1-MDCK cells as compared with that in wild-type MDCK cells.
The cognition of both P-gp and OCT to business a wide geological formation of organic cations, as demonstrated in experimental models, may explain the high rate of tubular biological process and knowledge to characterize diffusion maxima for some cationic drugs in vivo.
In our knowledge domain, we found that itraconazole and PSC-833, both known inhibitors of P-gp, reduced the basolateral-to-apical diffusion of cimetidine.
The concentrations of PSC-833 (0.5 µmol/L) and itraconazole (0.1-2.0 µg/ml) used in this acquisition were INSTANCE OFKorea based on concentrations achieved in clinical studies. Interestingly, both agents reduced the basolateral-to-apical business enterprise and efflux ratios of cimetidine at clinically achievable concentrations in the MDR1-MDCK hypothesis.
Thus, it appears that use of P-gp inhibitors such as itraconazole and PSC-833 may obstructor renal drug waste, resulting in systemic step-up and perniciousness.
This is a part of article Evaluation of P-glycoprotein-Mediated Renal Drug. Taken from "Discount Allegra Fexofenadine" Information Blog
Thursday, October 25, 2007
Evaluation of P-glycoprotein-Mediated Renal Drug.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment